plasma new
plasma collect impact remain insul
rel procedur broadli recoveri take shape
confid plasma durabl evid
nexsi traction increas convict remain overweight
quarter report revenu organ
pre-covid estim due time pandem
progress compani state limit impact seen
result experienc impact product avail date plasma
organ growth modestli ahead estim due
favor price volum plasma impact limit dispos
sale final week march adjust union divestitur exit
liquid solut inorgan impact plasma revenu normal
blood center revenu normal beat estim
driven rapid spike demand blood product discuss
modestli off-set hospit revenu normal
light estim china revenu declin elect
procedur deferr impact north america revenu margin
bp y/i bp light estim adjust covid impact ep
miss estim although adjust covid impact
ep rel line
plasma collect new normal state plasma
collect volum april run prior
plan despit manag state rebound alreadi seen may
new normal look like variou action taken center
improv donor psycholog enhanc clean protocol
enforc social distanc requir consist dilig
could lower effect capac like enter recessionari period
taken view plasma collect may insul given heighten
unemploy typic lead greater donor propens see
consist manag commentari plasma center innat
greater flexibl compar hospit may extend oper hour
and/or rais donor payment necessari although forecast
provid manag reiter confid growth long-term
collect volum assum may june normal
respect would impli normal number
assum surg collect recov lost volum could upsid
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
therefor lower plasma estim organ may prove
conserv donat recov faster anticip
role plasma fight manag highlight three primari
role plasma fight on-going trial work straight
applic ivig use convalesc plasma hyperimmun
globulin via convalesc plasma latter two similar primari
custom base differ compani engag blood center custom
countri help collect convalesc plasma treat
manag see signific commerci opportun given limit
donor pool tight window recov donor elig rather
view moreso month bridg vaccin hyperimmun globulin
concentr therapeut convalesc plasma relev
plasma fraction
impact like sever due uncertainti durat associ
provid guidanc state
intent issu guidanc later year although impact
gener limit compani forecast acut
impact specif result extent compani
reaffirm lrp ebit see prudent given model
current impli ebit note highli depend acut
revenu impact recoveri mitig effort cadenc cost save
initi discuss key segment dynam
nexsi discuss lower underli plasma estim
given recent trend collect volum nexsi
placement argument placement acceler
postpon manag see current environ conduc
custom wish increas throughput therefor nexsi valu
proposit remain high commentari also suggest compani
current process nexsi convers may indic new
custom contract believ repres grifol
convers oppos argument would convert full system
fleet may top custom prioriti acut period
disrupt discuss previous still see forese larg custom
contract come vs see
hospit discuss segment revenu normal
procedurally-expos peer averag note china
repres hospit segment revenu manag cite
declin china point adjust revenu in-
line devic peer normal april manag
disclos across hospit segment revenu
assum gradual recoveri given segment
procedurally-expos arriv normal model
organ growth segment
blood segment revenu normal attribut
influx demand custom built blood product inventori
safeti stock like continu like taper
remain lumpi throughout year model flat organ growth
competit loss combin underli declin may off-set
inventori build year model organ growth
underli point impact competit loss
save liquid expect compani reduct
initi program complet manag reiter
commit deliv cost save
oper excel program major drop
bp margin expect updat save realiz
program time guidanc similar corpor manag
highlight variou initi beyond oep manag cost includ
restrict travel reduc nonessenti spend inventori manag
review capital-expenditure project among other term liquid
exist credit facil place debt drawn fiscal year-
end april compani borrow addit revolv
bring total cash balanc pro-forma gross leverag ratio
coven allow facil matur
major repay weight toward end term
capit alloc compani buy-back author remain
surpris manag anticip repurchas addit
stock
plasma remain debat remain overweight view
phase recoveri asset within phase recoveri model given plasma
collect fare insul acut period disrupt
combin faster recoveri alreadi demonstr
compani remain well capit underli thesi signific margin
inflect remain intact cost save program drive bp
margin remain overweight price target base
ebitda estim discount back one year reflect financi
impact contract repres five-turn premium peer
see defens given above-p organ growth materi
million except ep
sale
sale
sale
sale
sale
sale
price target reect ebitda discount back one year
ve-turn premium smid cap peer given superior organ growth prole materi
plasma collect volum unaffect
upsid nexsi price cost
save drop balanc sheet
achiev per liter increment
plasma price nexsi greater cost
save drop balanc sheet
deploy drive materi upsid
beyond
abl
nexsi achiev two larg
custom contract save
provid durabl margin leverag
stori tie long-
rang plan lrp doubl oper
incom quadrupl
turnaround primarili lever nexsi
compani next-gen plasma apheresi
nexsi valu creation materi withth
yield opportun appreci see
posit backdrop nexsi drive
valu per liter plasma
custom expect
share prot increment per
liter price indic nexsi alon
drive lrp object
drive materi inect
view descript risk reward theme
growth next nexsi
unabl gain materi price benet
nexsi unabl creat materi valu
custom and/or unabl
program unabl achiev materi
drop-through initi expect due
nexsi drive increment valu per
liter plasma custom haemonet
expect particip prot share
oper excel program
drive bp margin year
china india
view explan region hierarchi
research highest favor quintil
larg custom contract come earlier
consensu anticip
save program continu drive
impact plasma donat
larg custom declin convert nexsi
save program fail materi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
equival
accum comprehens incom
dollar million except per share data
loss asset dispos
chang work capit
net provid oper activ
capit intang asset
sale properti invest
net use invest activ
chang equiti
net financ activ
net chang
equival bop
equival eop
